Welcome to the webpage for the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology at the University of Alabama at Birmingham School of Medicine. The Division serves as the major referral center for patients with a gynecologic cancer in the state of Alabama. We are a multidisciplinary team of specialty physicians, nurses, and consultants providing comprehensive, compassionate care in treating women's cancers. Our faculty members are board-certified, award-winning physicians who are national and international leaders in gynecologic cancer. Faculty members in the Division have been recognized by their physician peers and patients in US News and World Report, the American Cancer Society, Patient's Choice Awards, the Lynne Cohen Foundation, and the Ovarian Cancer National Alliance. The Division provides access to immediate consultations, ovarian and endometrial cancer risk assessment, advanced abdominal-pelvic and robotic surgical procedures, expert gynecologic cancer pathologists, comprehensive chemotherapy infusion services, rapid radiation oncology consultations, cutting edge clinical trials, and supportive care services. All of these services are made available in the Division's clinic within the Women and Infant's Center.
Education is also a key mission of the Division. The Division actively participates in the training of medical students and residents within the Department. The Division has a well established Fellowship training program. The Fellowship is structured to provide fellows comprehensive clinical and surgical training and to prepare each fellow for a career in academic gynecologic oncology. The fellowship selection process identifies candidates with clinical and surgical aptitude, as well as interest and demonstrated ability in basic, translational or clinical research.
The Division has an extensive portfolio of funded basic and translational research in gynecologic cancer. The Division was a founding member of the NCI funded Gynecologic Oncology Group (GOG) and offers our patients access to cutting edge clinical trials sponsored by the GOG and other leading pharmaceutical companies. The Division is well known for its ovarian cancer research in gene therapeutics and novel monoclonal antibodies and previously held a NCI funded Ovarian Cancer Special Program of Research Excellence (SPORE). The Division is also well know for its expertise in cervical cancer prevention and treatment and currently holds, in collaboration with Johns Hopkins, the only NCI funded Cervical Cancer SPORE.
The volume of patients, the excellence in education, and the breadth and depth of research in gynecologic cancers truly distinguishes the Division as one of the leaders in gynecologic cancer in the country.